Lerzam

Lercanidipine, the active ingredient in Lerzam, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension, helping to reduce cardiovascular risk and improve overall health outcomes.

GNH USA supplies Lerzam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, offering consistent product availability, regulatory support, and responsive technical assistance.

Lercanidipine is a calcium channel blocker used to manage arterial hypertension and related blood‑pressure disorders.

- Hypertension: Lowers systolic and diastolic blood pressure, helping patients reach target levels. - Essential hypertension: Provides sustained blood‑pressure control in primary hypertension. - Isolated systolic hypertension: Reduces elevated systolic pressure, particularly in older adults.

Lercanidipine may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: Mild to moderate pain often occurring after dose initiation. - Flushing: Warm sensation and redness of the skin, especially on the face. - Peripheral edema: Swelling of the ankles or lower legs. - Dizziness: Light‑headedness, particularly when standing quickly. - Tachycardia: Increased heart rate, usually transient. - Fatigue: General feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: Marked drop in blood pressure leading to fainting. - Myocardial infarction: Rare occurrence of heart attack. - Angioedema: Swelling of the face, lips, or throat requiring urgent care. - Hepatic injury: Uncommon liver enzyme elevations. - Severe allergic reaction: Rash, itching, or anaphylaxis. - Cardiac arrhythmia: Irregular heart rhythm in susceptible individuals.

Before prescribing Lercanidipine, clinicians should consider several safety measures.

- Monitor blood pressure: Check regularly to avoid excessive hypotension. - Assess hepatic function: Use caution in patients with liver impairment. - Review concomitant antihypertensives: Adjust doses to prevent additive effects. - Avoid abrupt discontinuation: Taper gradually to reduce rebound hypertension. - Evaluate CYP3A4 inhibitors: Dose may need adjustment when strong inhibitors are co‑administered. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase plasma levels and risk of hypotension. - Grapefruit juice: Potentiates drug exposure, leading to excessive blood‑pressure lowering. - Other potent vasodilators: Combined use can cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Can blunt antihypertensive response. - Diuretics: May enhance diuretic‑induced electrolyte changes. - Beta‑blockers: Requires careful blood‑pressure monitoring.